How are you using liquid biopsy in the routine management of your patients with metastatic NSCLC?   

Are you using ctDNA blood tests for targetable mutations at the time of diagnosis, at the time of disease progression, or not at all?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution